

Product Datasheet

TA-8995

Catalog No. **BP-02092** · CAS **866399-87-3** · Form **free base** · Physical state **other** · Color **white to light yellow** · Version **1.0** · Revision **2026-09-14**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target CETP; Apolipoprotein; LPL Receptor; LDLR	Research area Cardiovascular Disease
---	--

Molecular formula **C₃₂H₃₁F₉N₄O₅**

Molecular weight **722.5980**

STRUCTURE



DESCRIPTION

Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

BIOLOGICAL ACTIVITY

In Vitro

Obicetrapib is a weak inducer of CYP3A4, but it has no significant effect on P-gp activity, and has good safety and tolerability.

SOLUBILITY

Soluble in DMSO ≥ 100 mg/mL

REFERENCES

[1]. Kastelein JJP, et al. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024;26(2):35-44.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.